USFDA issues 10 observations for Zydus Lifesciences Jarod facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-04-24 10:31 GMT | Update On 2024-04-24 10:31 GMT
Advertisement
Ahmedabad: Zydus Lifesciences has informed in a BSE filing that the US Food and Drug Administration (USFDA) has concluded an inspection with 10 observations at the Company's Injectable Manufacturing site situated at Jarod, near Vadodara.
The inspection was conducted from April 15 to April 23, 2024.
"The Company will closely work with the USFDA to address and respond to the observations in an expeditious manner," Zydus stated in a BSE filing.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.